Literature DB >> 29307565

Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris.

Elizabeth L Berkow1, Shawn R Lockhart2.   

Abstract

CD101 is a new echinocandin with a prolonged half-life. CD101 was tested by broth microdilution against 100 isolates of the emerging yeast Candida auris. It showed activity against most isolates, including some that were resistant to other echinocandins. Published by Elsevier Inc.

Entities:  

Keywords:  CD101; Candida auris; Echinocandin

Mesh：

Substances：

Year:  2017        PMID： 29307565     DOI： 10.1016/j.diagmicrobio.2017.10.021

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  31 in total

1.  Rapid Detection of ERG11-Associated Azole Resistance and FKS-Associated Echinocandin Resistance in Candida auris.

Authors:  Xin Hou; Annie Lee; Cristina Jiménez-Ortigosa; Milena Kordalewska; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method.

Authors:  Marie Helleberg; Karin Meinike Jørgensen; Rasmus Krøger Hare; Raluca Datcu; Anuradha Chowdhary; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.

Authors:  Alexander J Lepak; Miao Zhao; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 4.  Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents.

Authors:  Sahar Hasim; Jeffrey J Coleman
Journal:  Future Med Chem       Date:  2019-04-17       Impact factor: 3.808

Review 5.  Emerging and future strategies in the management of recalcitrant Candida auris.

Authors:  Nihal Bandara; Lakshman Samaranayake
Journal:  Med Mycol       Date:  2022-03-17       Impact factor: 4.076

6.  Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.

Authors:  Milena Kordalewska; Annie Lee; Steven Park; Indira Berrio; Anuradha Chowdhary; Yanan Zhao; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

7.  Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.

Authors:  Alexander J Lepak; Miao Zhao; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

8.  Adaptation of the emerging pathogenic yeast Candida auris to high caspofungin concentrations correlates with cell wall changes.

Authors:  Violeta Lara-Aguilar; Cristina Rueda; Irene García-Barbazán; Sarai Varona; Sara Monzón; Pilar Jiménez; Isabel Cuesta; Ángel Zaballos; Óscar Zaragoza
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 9.  Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory.

Authors:  C Keighley; K Garnham; S A J Harch; M Robertson; K Chaw; J C Teng; S C-A Chen
Journal:  Curr Fungal Infect Rep       Date:  2021-06-23

10.  Clade distribution of Candida auris in South Africa using whole genome sequencing of clinical and environmental isolates.

Authors:  Serisha D Naicker; Tsidiso G Maphanga; Nancy A Chow; Mushal Allam; Stanford Kwenda; Arshad Ismail; Nelesh P Govender
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.